Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer

• Published in: International journal of molecular sciences 2022-04, Vol.23 (8), p.4408
• Main Authors: Bajbouj, Khuloud, Qaisar, Rizwan, Alshura, Mohammed A, Ibrahim, Zeinab, Alebaji, Mohamad B, Al Ani, Amenah W, Janajrah, Hanadi M, Bilalaga, Mariah M, Omara, Abdelrahman I, Abou Assaleh, Rebal S, Saber-Ayad, Maha M, Elmoselhi, Adel B
• Format: Article
• Language: English
• Subjects: Angiogenesis; Angiogenesis Inhibitors - pharmacology; Angiogenesis Inhibitors - therapeutic use; Antiangiogenics; Apoptosis; Assaying; Blood vessels; Breast cancer; Breast Neoplasms - metabolism; Cancer therapies; Caspase-9; Cell Line, Tumor; Cell Proliferation; Cell viability; Dosage; Drug dosages; Drug interaction; Endothelial cells; ErbB-2 protein; Estrogens; Extracellular signal-regulated kinase; Female; Growth factor receptors; Growth factors; Humans; Inhibitor drugs; Kidney cancer; Kinases; Metastases; Metastasis; Mortality; Neovascularization, Pathologic - drug therapy; Phenylurea Compounds; Progesterone; Proteins; Pyridines; Quinolines; Survival; Survivin; Targeted cancer therapy; Thyroid gland; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - metabolism; Vascular endothelial growth factor receptors; Vascularization; Western blotting
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23084408

Background: Breast cancer currently affects more than two million women worldwide, and its incidence is steadily increasing. One of the most essential factors of invasion and metastasis of breast cancer cells is angiogenesis and non-angiogenic vascularization. Lenvatinib and Regorafenib share the same anti-angiogenic effect by inhibiting vascular endothelial growth factor receptors (VEGFRs subtypes 1 to 3) and have been approved for treating different types of cancer. Methods: We investigated Lenvatinib and Regorafenib effects on a well-established in-vitro model of breast cancer using MCF-7 (estrogen, progesterone receptor-positive, and HER2-negative), MDA-MB-231 (triple negative), as well as Human Umbilical Vascular Endothelial Cell line (HUVEC) cell lines. We performed the cell viability assay on four groups of cells, which included a control group, a Lenvatinib treated only group, a Regorafenib treated only group, and a group treated with a combination of both drugs at 24, 48, and 72 h. Data were analyzed as means ± standard deviation, and the drug−drug interactions with Compusyn software. Cellular migration assay, tube formation assay, and Western blots were conducted to determine the functional and the protein expression of downstream signals such as Caspase-9, anti-apoptotic Survivin, P-ERK, and total-ERK in the control and treatment groups. Results: MCF-7 cells showed a reduction in cell survival rates with higher dosing and longer incubation periods with each drug and with the combination of drugs. A synergistic interaction was identified (CI < 1) with both drugs on MCF7 at different dose combinations and at a higher dose in MDA-MB-231 cells. Furthermore, there was a marked decrease in the anti-angiogenic effect of both drugs in tube formation assay using MDA-MB-231 cells and survivin protein expression in MCF-7, and those antitumor markers showed a better outcome in drug combination than the use of each drug alone. Conclusion: Our result is the first to report the synergistic anti-angiogenic potential of combination therapy of Lenvatinib and Regorafenib. Therefore, it shows their therapeutic potential in breast cancer, including the aggressive types. Further studies are warranted to confirm and explore this therapeutic approach.